is feeling shroomy
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Really simple. Reverse split then short squeeze. Nothing more to it.
The deal is what brought me back. We were questioning how they would fund expansion. They answered. Trading with emotion would be buying because you like the long term outlook for the company and selling because it had a bad day after a long rally that faced practically no resistance
Dips are opportunities!
The whole sector is going to grow together. One stock's strong performance doesn't negate another's potential.
A consolidation day like this was inevitable after the move we made while the CSE was closed.
I'm increasing my positioning in the sector. There is zero aspect of MindMed that screams "hocus pocus". These are both incredibly solid companies who are literally just getting started.
Chart is ripe. Just need news.
Spent nearly the full day above that huge high created on Friday. What an incredible display of strength for this stock.
Everyone wants their piece of the shroom pie!
We recently uplisted to OTCQB. Next up would be the QX international. Some benefits of uplisting are your exposure to new markets and better regulatory measures.
Requirements
https://www.otcmarkets.com/corporate-services/get-started/otcqx-international
More information on the QX market
https://www.otciq.com/services/otcqx-us
Interview with SHRMF CEO Roger McIntyre https://psilocybinalpha.com/news/interview-with-roger-mcintyre-champignon-brands
MindMed reports first quarter 2020 results
https://www.otcmarkets.com/stock/mmedf/news/MindMed-Reports-First-Quarter-2020-Results-and-Corporate-Update?id=262023
Or maybe it was a response to the earnings they released today in conjunction with a minor pullback after a 30% rally. You sold SHRMF on april 15 because they didn't immediately release the full terms of a just announced deal. Since then, they have increased market cap by 100%. They also rallied about 36% before a 13% pullback.
It is somewhat baffling how a couple of these psychedelic plays ignore the general market trends. S&P sheds 30 points as this trades near day's high.
MMEDF NEWS 5/11/2020:
MindMed Advances Phase 2 LSD Microdosing Trial For Adult ADHD, Appoints Principal Investigator
Signs Clinical Trial Agreement With Maastricht University In Netherlands
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
TORONTO, May 12, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED; OTC: MMEDF) ("MindMed" or the "Company") is pleased to announce that, on May 8, 2020, it has entered into a clinical trial agreement with Maastricht University to undertake a Phase 2a clinical trial for lysergic acid diethylamide ("LSD") in adult patients with Attention Deficit Hyperactivity Disorder ("ADHD"). MindMed previously established a microdosing division to develop a portfolio of clinical trials studying the use of sub-perceptual amounts of psychedelic substances for medical purposes.
As part of the agreement, Maastricht University will provide facilities and personnel for the Phase 2a Proof of Concept Clinical Trial for MindMed's multicentre, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of low dose LSD as treatment for ADHD in adults.
Dr. Kim Kuypers, associate professor, Department of Neuropsychology & Psychopharmacology at Maastricht University will serve as a Principal Investigator for the Phase 2a Clinical Trial. Dr. Kuypers is a leading clinical investigator in the field of psychedelics and has previously evaluated the concept of microdosing in other research. Her main goal as a clinical researcher is to understand the neurobiology underlying flexible cognition, empathy, and well-being.
MindMed is now advancing its LSD microdosing program with both Dr Kuypers and the previously announced partnership with University Hospital Basel's Liechti Lab. MindMed is currently in the regulatory ethics submission process in the Netherlands and plans to begin the Phase 2a clinical trial by the end of the year.
MindMed Co-Founder and Co-CEO, JR Rahn, said, "Working with Dr. Kim Kuypers, one of the leading research experts for microdosing of psychedelics, has the potential to help millions of adults through the development of innovations for coping and treating ADHD. Our work in the Netherlands will complement our existing collaboration with University Hospital Basel's Liechti Lab to better understand the therapeutic potential of microdosing."
Nice! I didn't know that board existed, thanks!
Our friends at the CSE hit their all time high today. Nice response to the news.
I'm glad we get immediate results from the PP. It's almost like they needed to announce the PP before they could announce the acquisition. Decent terms incentivizing a smooth integration to maximize top line revenue.
Yeah. I thought that was a bit bizarre as well.
Overall, this is good news for the company. The IPO 3 months ago was valued at .15/share. Private placement is .85/share. Private investors seem to think it's a good value here. They are putting proceeds to good use.
You are probably right at this point.
Almost 200k on the bid at 1.05 and more than on the ask now. Been refreshing every few minutes and the bid keeps growing.
https://thecse.com/en/listings/diversified-industries/champignon-brands-inc
I would think so. Management has done an excellent job with communication. Seems whoever has caught wind of the pending news is wanting to load up on the CSE.
Time will tell
Bids up 6% on the CSE. Eyes open.
https://thecse.com/en/listings/diversified-industries/champignon-brands-inc
Continuation this week speaks to the continued flow of news specific to growth strategy. It seems this company is firing on all cylinders.
A fantastic week for Champignon.
Acquisition complete and revenue stream announced.
https://www.otcmarkets.com/stock/SHRMF/news/Champignon-Ketamine-Treatment-to-be-Dispensed-by-Major-Canadian-Pharmacy-Chain-Closes-AltMed?id=260546
Market interest appears to be picking up. Nice volume and less volatility a sign of accumulation.
Uplist complete! https://www.otcmarkets.com/stock/SHRMF/overview
$MMEDF officially uplisted to OTCQB. They submitted their uplist documents on April 8, taking 9 days, or 6 business days. Barring no issues with the submission, SHRMF should uplist by next Friday if following the same timeframe. Since uplisting isn't automated, this could take a little bit shorter or a little bit longer.
https://www.otcmarkets.com/stock/SHRMF/disclosure
Interim financial statement and OTCQB certification published today.
Can't believe this is finally happening! Congrats to all who held strong :)
Matheau J. W. Stout is now on the list of prohibited service providers. Anyone know why? Hopefully AMFE addresses this soon as we now have Prohibited Service Provider cautioned under our Verified Profile badge on otcmarkets
Been waiting for this day for a long while now. Cheers to everyone.
Several subs? Please name them. Definition of several is more than 2...